ONCOLOGY Current Issue: August 2010 Vol 24 No 9

Article

The journal ONCOLOGY: Perspectives on Best Practices is a peer-reviewed open access reviews journal that focuses on practical treatment issues. Reviews are accompanied by insightful commentaries from oncologists working in a variety of settings.  

The journal ONCOLOGY: Perspectives on Best Practices is a peer-reviewed open access reviews journal that focuses on practical treatment issues. Reviews are accompanied by insightful commentaries from oncologists working in a variety of settings.
 

CURRENT ISSUE

July 2013  |  Volume 27 • Number 7

Recent Videos
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Vinay K. Puduvalli, MD, is featured in this series.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Related Content
The IPSS-del(5q) Scoring System shows that factors including male sex, cytopenias, and complex genetic background worsen the prognosis of MDS-del(5q).

Novel Scoring System May Improve Risk Stratification in MDS Subtype

Russ Conroy
December 9th 2024
Article

The IPSS-del(5q) Scoring System shows that factors including male sex, cytopenias, and complex genetic background worsen the prognosis of MDS-del(5q).

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Low Dose Deferasirox Yields Promising Transfusion Independence in MDS

Low Dose Deferasirox Yields Promising Transfusion Independence in MDS

Tim Cortese
December 9th 2024
Article

For patients with MDS who are relapsed/refractory to erythropoietin stimulating agents, low-dose deferasirox demonstrated promising efficacy and tolerability outcomes.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

All evaluable patients achieved minimal residual disease negativity following teclistamab-based treatment in the phase 3 MajesTEC-4/EMN30 trial.

Maintenance Teclistamab Yields Preliminary Activity in NDMM

Jason M. Broderick
December 9th 2024
Article

All evaluable patients achieved minimal residual disease negativity following teclistamab-based treatment in the phase 3 MajesTEC-4/EMN30 trial.

Acalabrutinib-based treatment also improves overall survival vs standard chemoimmunotherapy in the phase 3 AMPLIFY trial.

PFS Significantly Improves With Acalabrutinib Regimen in Untreated CLL

Kristie L. Kahl
December 8th 2024
Article

Acalabrutinib-based treatment also improves overall survival vs standard chemoimmunotherapy in the phase 3 AMPLIFY trial.